Evaluating the efficiency of THERA-101 as a treatment for Keratoconjunctivitis sicca (KCS) in dogs

The University of Florida College of Veterinary Medicine is currently recruiting dogs diagnosed with Keratoconjunctivitis sicca (KCS) or dry eye disease for a clinical research trial.

Enrollment Status: Currently Enrolling

Inclusion Criteria: Dogs diagnosed with Keratoconjunctivitis sicca (KCS) or dry eye disease are eligible to be enrolled. To participate, the dog must undergo a complete ophthalmic examination that includes measuring the amount and quality of tears produced.

Treatment: Your dog will receive the study medication topically as an eye drop. Owners or caretakers will be asked to give the medication as directed three times daily throughout the course of the study and return for recheck examinations 3 weeks, 6 weeks and 12 weeks from the beginning of the study.

During recheck visits, patients will undergo a routine eye examination to measure the amount and quality of tears. Additionally, we will collect tear fluid for laboratory analysis to assess tear quality through an assessment called tear ferning. This involves placing a pipette at the corner of the eyelids to collect fluid.  

Costs: The study will cover the cost of three (3) recheck examinations. The study medication will also be provided free of charge for the duration of the study. No other costs will be covered. 

Contact:  You can contact Dr. Caryn Plummer at (352) 278-1203 or at plummerc@ufl.edu to schedule an evaluation, or complete the Study Interest Form to see if your dog qualifies.

PI: Dr. Caryn Plummer

Background:  Keratoconjunctivitis sicca (KCS) or dry eye disease is a very common and important disease affecting both dogs and humans. The purpose of this study is to evaluate a new medication to improve comfort and decrease the damage that can be done to the surface of the eye as a consequence of this condition.